Rasheed Walid, Bishton Mark, Johnstone Ricky W, Prince H Miles
Division of Haematology & Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, Victoria 8006, Australia.
Expert Rev Anticancer Ther. 2008 Mar;8(3):413-32. doi: 10.1586/14737140.8.3.413.
Histone deacetylase inhibitors (HDACi) are a new class of antineoplastic agents with demonstrable preclinical antitumor activity in both in vitro and in vivo studies in a wide range of malignancies. Based on these preclinical findings, in recent years HDACi have undergone a rapid phase of clinical development with many HDACi entering Phase I-III clinical trials, both as single agents and in combination with other therapies. Favorable clinical responses have been demonstrated in cutaneous T-cell lymphoma with emerging evidence of clinical activity in other types of lymphoma and, to date, a good toxicity profile. Solid tumor responses to single agent and combination therapies have also been reported, paving the way for larger studies in this field. In this review we discuss the recent advances in the clinical development of HDACi and their current therapeutic role in lymphoma and solid malignancies.
组蛋白去乙酰化酶抑制剂（HDACi）是一类新型抗肿瘤药物，在多种恶性肿瘤的体外和体内研究中均显示出明显的临床前抗肿瘤活性。基于这些临床前研究结果，近年来HDACi经历了快速的临床开发阶段，许多HDACi已进入I - III期临床试验，既作为单一药物，也与其他疗法联合使用。在皮肤T细胞淋巴瘤中已证明有良好的临床反应，在其他类型淋巴瘤中也有临床活性的新证据，并且迄今为止，其毒性特征良好。也有关于实体瘤对单一药物和联合疗法反应的报道，为该领域的更大规模研究铺平了道路。在本综述中，我们讨论了HDACi临床开发的最新进展及其目前在淋巴瘤和实体恶性肿瘤中的治疗作用。
